Belatacept and mediastinal histoplasmosis in a kidney transplant patient.

about

Histoplasmosis in transplant recipients.

P2860

Q40043530-0461F34E-5CC0-4B89-84E0-07B05DB31A83

P2860

Belatacept and mediastinal histoplasmosis in a kidney transplant patient.

Item

http://www.wikidata.org/entity/Q36835315

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Belatacept and mediastinal histoplasmosis in a kidney transplant patient.

@en

type

Item

label

Belatacept and mediastinal histoplasmosis in a kidney transplant patient.

@en

prefLabel

Belatacept and mediastinal histoplasmosis in a kidney transplant patient.

@en

P1476

Belatacept and mediastinal histoplasmosis in a kidney transplant patient.

@en

P2093

Agustina Forastiero

http://www.w3.org/2001/XMLSchema#string

Alejandro Iotti

http://www.w3.org/2001/XMLSchema#string

Fernando Lombi

http://www.w3.org/2001/XMLSchema#string

Hernán Trimarchi

http://www.w3.org/2001/XMLSchema#string

Iris Agorio

http://www.w3.org/2001/XMLSchema#string

José Andrews

http://www.w3.org/2001/XMLSchema#string

Mariano Forrester

http://www.w3.org/2001/XMLSchema#string

Matías Paulero

http://www.w3.org/2001/XMLSchema#string

Romina Iriarte

http://www.w3.org/2001/XMLSchema#string

Tatiana Rengel

http://www.w3.org/2001/XMLSchema#string

P2860

CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response

Post-transplant aspergillosis and the role of combined neurosurgical and antifungal therapies under belatacept immunosuppression

Histoplasmosis after solid organ transplant.

Summary of the US FDA approval of belatacept.

Belatacept: in adult kidney transplant recipients.

Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down.

Histoplasmosis in renal transplant patients in an endemic area at a reference hospital in Medellin, Colombia.

Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area.

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

P304

84-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.15171/JNP.2016.15

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

301641009

http://www.w3.org/2001/XMLSchema#string

P698

27152295

http://www.w3.org/2001/XMLSchema#string

P932

4844914

http://www.w3.org/2001/XMLSchema#string

Belatacept and mediastinal histoplasmosis in a kidney transplant patient.

about

P2860

P2860

Belatacept and mediastinal histoplasmosis in a kidney transplant patient.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932